A unique characteristic of Helicobacter pylori could serve to end infections of this gastric bacterium. A group of scientists from the University of Munich have found that this pathogen has a strategic point in its mitochondrial respiratory complex I that could be targeted with inhibitors. “We did not look for respiration inhibitors in the first place,” co-senior author Wolfgang Fischer told BioWorld. “We screened libraries with a reporter assay, looking for something different, a particular protein secretion, the secretion system type (T4SS). Then, we found that a lot of compounds inhibit this process. From these compounds, we came to the point that they are actually respiration inhibitors,” he explained.
Researchers at NYU Langone Health and Janssen Biotech Inc. have reported on mAbtyrins, bioengineered molecules composed of human monoclonal antibodies and centyrins that are a new way to fight Staphylococcus aureus infection on all fronts.In their experiments, which were published in Cell Host & Microbe on April 24, 2023, the team described mAbtyrin, as “a protein-based therapeutic that targets 10 disease-causing mechanisms employed by S. aureus,” senior author Victor Torres told BioWorld.
Janssen R&D (Ireland) has described respiratory syncytial virus (RSV) inhibiting spiro-bearing derivatives reported to be potentially useful for the treatment of RSV infections.
Akthelia Pharmaceuticals ehf and the University of Iceland have announced the successful joint award of a €6 million (US$6.6 million) EU Horizon Grant to fund the IN-ARMOR project that seeks to address antimicrobial resistance (AMR).
Clevudine derivatives and its phosphoramidates have been detailed in an Emory University patent as potentially useful for the treatment of hepatitis B virus (HBV) infection.
Research at Pardes Biosciences Inc. has led to the identification of cysteine protease inhibitors, particularly 3C-like proteinase (3CLpro, Mpro, nsp5; SARS-CoV-2) and Mpro (HCoV-229E virus) inhibitors, reported to be useful for the treatment of viral infections.
Veru Inc. announced results from an in vitro study evaluating the effects of sabizabulin against a prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells.
RSS
